JEIL PHARMA HOLDINGS INC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10,200 KRW | +0.89% |
|
+0.20% | -13.34% |
| 2023 | Jeil Pharma Holdings Inc Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
| 2022 | Jeil Pharma Holdings Inc's Equity Buyback Plan Extended till October 2, 2042. | CI |
| Sales 2022 | 793B 580M | Sales 2023 | 804B 588M | Capitalization | 181B 132M |
|---|---|---|---|---|---|
| Net income 2022 | -74.56B -54.5M | Net income 2023 | -16.25B -11.88M | EV / Sales 2022 | 0.44 x |
| Net Debt 2022 | 109B 79.83M | Net Debt 2023 | 155B 113M | EV / Sales 2023 | 0.42 x |
| P/E ratio 2022 |
-3.17
x | P/E ratio 2023 |
-11.1
x | Employees | 39 |
| Yield 2022 |
0.32% | Yield 2023 |
0.42% | Free-Float | 13.57% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.89% | ||
| 1 week | +0.20% | ||
| Current month | -0.20% | ||
| 1 month | -7.27% | ||
| 3 months | -1.73% | ||
| 6 months | -16.05% | ||
| Current year | -13.34% |
1 week
10 050.00
10 350.00
1 month
10 050.0011 370.00
Current year
9 760.0012 380.00
1 year
9 250.0014 360.00
3 years
9 100.0026 500.00
5 years
7 970.0033 000.00
10 years
7 970.00139 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sang-Cheol Han
CEO | Chief Executive Officer | 48 | - |
Bong-Hui Moon
BRD | Director/Board Member | 72 | - |
Jae-Hyeon Kim
PRN | Corporate Officer/Principal | 53 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sang-Cheol Han
CEO | Chief Executive Officer | 48 | - |
Bong-Hui Moon
BRD | Director/Board Member | 72 | - |
Dong-Yeol Lee
BRD | Director/Board Member | 62 | 21-03-22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-05 | 10,200 | +0.89% | 6,036 |
| 24-06-04 | 10,110 | -2.03% | 17,201 |
| 24-06-03 | 10,320 | +0.98% | 3,862 |
| 24-05-31 | 10,220 | +0.39% | 2,068 |
| 24-05-30 | 10,180 | -2.49% | 8,924 |
End-of-day quote Korea S.E., June 04, 2024
More quotes
JEIL PHARMA HOLDINGS INC., formerly Jeil Pharmaceutical Co.,Ltd is a Korea-based company mainly engaged in the manufacture and distribution of pharmaceuticals. The Company provides antibiotics, anti-inflammatory painkillers, hepatitis remedies, duodenum ulcer treatments, anticancer drugs, tristimania drugs, gastritis drugs, stomach ulcer drugs, septicemia treatments, pollakisuria treatments, acute bronchitis remedies, hyperlipidemia treatments and others. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-08
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -13.34% | 115M | |
| +16.91% | 42.33B | |
| +20.67% | 22.47B | |
| +16.96% | 15.25B | |
| +19.39% | 14.29B | |
| +52.16% | 12.6B | |
| -0.05% | 6.79B | |
| -11.09% | 6.71B | |
| -8.87% | 5.73B | |
| +14.27% | 5.47B |
- Stock Market
- Equities
- A002620 Stock
